Here is Why Growth Investors Should Buy Amneal (AMRX) Now

Core Viewpoint - Growth investors seek stocks with above-average financial growth, but identifying such stocks can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Amneal Pharmaceuticals (AMRX) is currently recommended as a growth stock based on its favorable Growth Score and top Zacks Rank [2] - The company has a historical EPS growth rate of 2%, but projected EPS growth for this year is expected to be 21.8%, significantly higher than the industry average of 14.3% [4] Group 2: Financial Metrics - Amneal's asset utilization ratio (sales-to-total-assets ratio) is 0.82, indicating that the company generates $0.82 in sales for every dollar in assets, outperforming the industry average of 0.44 [5] - The company's sales are projected to grow by 7.7% this year, compared to an industry average of 0% [6] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Amneal, with the Zacks Consensus Estimate for the current year increasing by 4.9% over the past month [8] - The combination of a Zacks Rank 2 and a Growth Score of B suggests that Amneal is positioned as a potential outperformer for growth investors [10]